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342 Abstract
43 Background
44 Oral P2Y12 inhibitors take more than 2 hours to achieve full effect in healthy subjects 
45 and this action is further delayed in patients with acute myocardial infarction. 
46 Intravenous (IV) P2Y12 inhibition might lead to more timely and potent anti-platelet 
47 effect in the context of emergency primary angioplasty, improving myocardial 
48 recovery.
49 Objectives
50 To compare the efficacy of IV cangrelor vs. ticagrelor in a STEMI population treated 
51 with primary percutaneous coronary intervention (PPCI). 
52 Patients/Methods
53 In an open-label, prospective, randomized controlled trial, 100 subjects with STEMI 
54 were assigned 1:1 to IV cangrelor or oral ticagrelor. The co-primary endpoints were 
55 platelet P2Y12 inhibition at infarct vessel balloon inflation time, 4 hours and 24 hours. 
56 Secondary endpoints included indices of coronary microcirculatory function: Index of 
57 microvascular resistance (IMR), initial infarct size (troponin at 24 hours) and final 
58 infarct size at 12 weeks (cardiac magnetic resonance-CMR). Corrected TIMI frame 
59 count (cTFC), TIMI Flow grade (TFG), myocardial perfusion grade (MPG) and ST-
60 segment resolution (STR). (ClinicalTrials.gov NCT02733341).
61 Results
62 P2Y12 inhibition at first balloon inflation time was significantly greater in cangrelor 
63 treated patients (cangrelor PRU 145.2 ± 50.6 vs. ticagrelor 248.3 ± 55.1). There was 
64 no difference in mean PRU at 4 hours and 24-36 hours post dosing. IMR, final infarct 
65 size, angiographic and electrocardiographic measures of reperfusion were all similar 
66 between groups.
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467 Conclusion
68 Cangrelor produces more potent P2Y12 inhibition at the time of first coronary balloon 
69 inflation time compared with ticagrelor. Despite this enhanced P2Y12 inhibition, 
70 coronary microvascular function and final infarct size did not differ between groups.
71 Key Words 
72 Antiplatelet, infarct size, microcirculation, myocardial infarction, percutaneous 
73 coronary intervention.
74 Abbreviations
75 Myocardial infarction (MI)
76 ST-segment elevation myocardial infarction (STEMI)
77 Primary percutaneous coronary intervention (PPCI)
78 Index of microvascular resistance (IMR)
79 Coronary flow reserve (CFR)
80 ST-segment resolution (STR)
81 Corrected TIMI frame count (cTFC)
82 TIMI flow grade (TFG)
83 Myocardial perfusion grade (MPG)
84 Cardiac magnetic resonance (CMR)
85 Intravenous (IV)
86
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587 What is known on this topic
88  Antiplatelet therapy with potent oral P2Y12 receptor antagonists improves
89 outcomes in STEMI with both ticagrelor and prasugrel showing superior
90 efficacy to clopidogrel.
91  One important limitation of all orally administered P2Y12 inhibitors is delayed
92 antiplatelet effect, which can take several hours to achieve in the setting of
93 STEMI. Therefore PPCI is likely to be performed in the context of sub-
94 optimal P2Y12 inhibition.
95  Cangrelor being a direct reversible P2Y12 inhibitor with rapid onset and offset
96 of action overcomes many of the limitations associated with oral P2Y12
97 inhibitors, making its use in the setting of acute STEMI undergoing primary
98 PCI where prompt antiplatelet inhibition is required, appealing.
99 What this paper adds
100  This study confirms that cangrelor produces early, potent P2Y12 inhibition in
101 patients treated with PPCI.
102  It supports the periprocedural administration of cangrelor in the setting of
103 primary PCI as a potential bridging IV antiplatelet therapy until the full
104 antiplatelet effect is achieved with oral P2Y12 receptor inhibitors. This
105 approach would help overcome the main issue encountered with oral P2Y12
106 inhibitors in the setting of primary PCI, which is their delayed onset of action.
107  In our cohort, acceptable levels of P2Y12 inhibition were achieved with oral
108 ticagrelor by 4 hours following loading, and in cangrelor treated patients, the
109 post PPCI transition to ticagrelor did not appear to lead to a significant
110 rebound in platelet activity.
111
112
113
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6115 Introduction
116 Coronary artery disease is the primary cause of premature mortality in the developed 
117 world and STEMI is its most lethal acute manifestation. [1] Antiplatelet therapy with 
118 potent oral P2Y12 receptor antagonists improves outcomes in STEMI with both 
119 ticagrelor and prasugrel showing superior efficacy to clopidogrel.  [2] One important 
120 limitation of all orally administered P2Y12 inhibitors is delayed antiplatelet effect, 
121 which can take several hours to achieve in the setting of STEMI. [3]
122 Cangrelor, an IV adenosine triphosphate analogue, has an onset of action of 1-3 
123 minutes and does not require metabolic transformation to become fully active. It 
124 induces marked platelet inhibition very rapidly and has a plasma half-life of just 3-6 
125 minutes. Three large randomized trials have compared its use to oral clopidogrel. [2] 
126 The CHAMPION PHOENIX showed cangrelor reduced the combined endpoint of 
127 death, MI, ischemia driven revascularization or stent thrombosis at 48 hours when 
128 compared to clopidogrel. The notion that earlier more potent P2Y12 inhibition will 
129 benefit patients undergoing PPCI is biologically plausible and is supported by the 
130 current ACC/AHA/ESC guidelines for ACS, which give a class 1 recommendation for 
131 early treatment with a P2Y12 inhibitor. [2]
132 A recent randomized pharmacodynamic study has assessed the antiplatelet effect of 
133 cangrelor vs. ticagrelor plus cangrelor at the time of PPCI in 30 patients, showing 
134 enhanced early P2Y12 inhibition in patients treated with both ticagrelor and cangrelor. 
135 Intriguingly, in this study, a proportion of the patients receiving both agents exhibited 
136 an increase in platelet reactivity after stopping the cangrelor infusion. [4] 
137 In the recently published CANTIC study, 50 patients undergoing PPCI received 
138 crushed ticagrelor and were then randomized to be treated with simultaneous 
139 cangrelor or matching placebo. Cangrelor reduced the PRU throughout the infusion, 
140 compared to placebo and consequently therefore high on-treatment platelet reactivity 
141 (HPR) rates were reduced in the cangrelor arm. After stopping the infusion, no 
142 rebound increase in platelet activity occurred, suggesting no drug-drug interaction. [5] 
143 The clinical importance of optimal P2Y12 inhibition at the time of PPCI remains 
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7144 incompletely explored, and in addition, safe transition from IV therapy to an oral 
145 P2Y12 inhibitor is an important issue. [6]
146 Even with timely PPCI, up to half of patients have limited microvascular perfusion 
147 despite restoration of normal epicardial flow.[7] These patients have larger infarcts [8] 
148 and are at higher risk of adverse events [9]. Recent studies highlight the role of 
149 platelets in contributing to microvascular dysfunction in the context of acute STEMI 
150 through various mechanisms including ischemia, reperfusion injury and distal 
151 embolization. [10].
152 We set out to determine the differential effect of cangrelor vs. ticagrelor on P2Y12 
153 inhibition at the time of first balloon inflation in the culprit coronary artery, and 
154 following PCI in a cohort of patients undergoing PPCI for STEMI. Additionally, we 
155 studied the impact of these two treatment strategies on a variety of measures of 
156 microvascular function and infarct size following PPCI.
157 Study Endpoints
158 The co-primary endpoints for this trial were the between-group difference in P2Y12 
159 inhibition at the time of first intracoronary balloon inflation, 4 hours and 24 hours 
160 following initial dosing. Secondary surrogate outcome measures were the assessment 
161 of microcirculatory and epicardial reperfusion in addition to myocardial infarct size.
162
163 Methods
164 Study Population and STEMI Management
165 This is an open label, prospective, randomized controlled trial enrolling patients with 
166 acute STEMI undergoing PPCI. Acute STEMI was defined as chest pain lasting 
167 for >30 minutes associated with ST-segment elevation >2 mm in 2 contiguous chest 
168 leads or 1mm in 2 contiguous limb leads. Following informed consent, subjects were 
169 randomized 1:1 to routine care (aspirin and ticagrelor) or aspirin and IV cangrelor 
170 immediately prior to PPCI. Patients were eligible if they had an indication for PPCI, 
171 were able to give informed consent, were P2Y12 receptor inhibitor naïve and had no 
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8172 contra-indication to ticagrelor or cangrelor. Exclusion criteria included significant 
173 active bleeding, current oral anticoagulation therapy, established cardiogenic shock, 
174 previous myocardial infarction (MI), and contraindications to CMR imaging. Patients 
175 treated with GP IIb/IIIa receptor antagonist therapy during PPCI were withdrawn 
176 from the analysis. All patients provided written consent and continued in the study for 
177 3 months. The study was approved by the UK National Research Ethics Service 
178 (reference 16/EM/0094). 
179 Drug Therapy
180 A total of 100 subjects were enrolled, 50 in the cangrelor arm and 50 in the ticagrelor 
181 arm. All patients received aspirin 300mg loading at the time of first medical contact, 
182 prior to randomisation. Patients allocated to ticagrelor received a loading dose of 180 
183 mg of the drug orally immediately following randomization and prior to admission to 
184 the catheter suite followed by a dose of 90mg twice daily for 12 months. Patients in 
185 the cangrelor arm were treated with a bolus of 30mcg/kg then 4mcg/kg/min IV 
186 infusion immediately following randomization and then transferred to the cardiac 
187 catheter suite to undergo PPCI. Cangrelor infusion was continued for 2 hours or for 
188 duration of the procedure; whichever was longer. Ticagrelor 180 mg was given 30 
189 minutes prior to stopping the infusion, as per manufacturers instructions, followed by 
190 a dose of 90mg twice daily for 12 months. Use of morphine was recorded 
191 prospectively. 
192 Primary Endpoint Measures
193 Platelet Function Testing
194 P2Y12 inhibition was measured using VerifyNow ™ (ACCRIVA diagnostics, San 
195 Diego, California, USA) rapid platelet function analyzer at the time of infarct vessel 
196 balloon inflation, 4 hours following study drug loading and at 24-36 hours. 
197 Results are expressed as P2Y12 reaction units (PRU), indicating the degree of ADP-
198 mediated aggregation specific to the P2Y12 receptor. PRU values of ≥208 are 
199 indicative of a suboptimal response and are associated with poor clinical outcomes 
200 including death, MI and stroke at one year. [11] 
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9201 Surrogate Endpoint Measures
202 Index of Micro-vascular Resistance and Coronary Flow Reserve 
203 IMR and Coronary Flow Reserve (CFR) were measured in the culprit coronary at the 
204 end of the PPCI procedure. IMR, a combined pressure-/temperature-tipped guidewire 
205 based quantitative assessment of coronary microvasculature function, is defined as the 
206 distal coronary pressure multiplied by the mean transit time of a 3-mL bolus of saline 
207 at room temperature measured simultaneously during maximal coronary hyperemia 
208 (Certus, ST Jude medical, St Paul Minnesota). [12] Maximal coronary hyperemia was 
209 induced with IV adenosine at a dose of 140 micrograms/kg/min. The dose was 
210 increased at operator’s discretion if there was a sub-optimal symptomatic or 
211 hemodynamic response at the standard dose. 
212 We set out to assess the absolute IMR values in each group and the proportion of 
213 subjects in each group with an IMR > 40.  CFR is calculated as the ratio of maximal 
214 blood flow during maximal coronary hyperemia to resting flow. It is influenced by 
215 both epicardial arterial and microvascular function. A CFR < 2.0 is considered 
216 abnormal and is associated with cardiovascular disease states. We report the mean 
217 CFR in each group. [13]
218 All physiological metrics were independently assessed by two experienced 
219 cardiologists at the University of Glasgow Physiology Core Laboratory (TF & CB) 
220 blinded to treatment group assignment.
221 Angiographic Analysis
222 Thrombolysis in Myocardial Infarction (TIMI) Flow Grade (TFG), Corrected TIMI 
223 Frame Count (cTFC) and TIMI Myocardial Perfusion Grade (MPG) were measured 
224 using standard techniques and a frame counter. [14]
225 ST-segment Resolution 
226 A 12 lead EKG was recorded before coronary reperfusion and 90-120 minutes 
227 following PPCI to assess ST-segment resolution (STR). This variable was expressed 
228 as complete (>70%), incomplete (>30% to < 70%) or none (<30%).[15]
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10
229 Initial Infarct Size Estimation by Peak Troponin Level
230 High sensitivity cardiac troponin T (cTnT) was measured at 24-36 hours following 
231 PPCI (Roche, Rotkreuz, Switzerland).
232 Final Infarct Size Assessment by CMR Imaging 
233 Patients were studied at 3 months post presentation using a 1.5 Tesla scanner (Philips 
234 Ingenia) with a standard 12-channel matrix coil configuration.[16] 
235 All measurements were performed by 2 observers (EM and SH, level 3 SCMR) 
236 blinded to clinical and angiographic data. Where a discrepancy of >10% was evident 
237 between reports, the final figure was reached by consensus. Image analysis for LV 
238 volumes, LV function and LV mass were performed using semi-automated software 
239 (CMR42 Circle Cardiovascular Imaging, Canada). Infarct size was expressed as a 
240 percentage of LV mass. 
241 Safety Endpoints
242 Bleeding events were prospectively assessed using the Bleeding Academic Research 
243 Consortium (BARC) criteria during the index admission. [17]
244 Statistics and Data Analysis
245 Categorical variables are reported as number and percentage (n (%)). Continuous 
246 variables are summarized by mean and standard deviation (SD) if normally 
247 distributed and median and interquartile range (IQR) if non-normally distributed. 
248 Continuous outcome measures were compared between groups with two sample t-
249 tests or Wilcoxon rank sum tests.  Categorical outcome measures were compared 
250 using Chi-squared tests or Fisher Exact tests.  All p-values are two-sided and 
251 statistical significant was considered as p≤ 0.05. Data were analyzed by the Robertson 
252 Centre for Biostatistics, University of Glasgow using SAS for windows v9.3 (SAS 
253 Institute Inc., Cary, North Carolina). Graphs were produced using Prism software 
254 (GraphPad Prism version 5.0, La Jolla Ca.). A sample size calculation was performed 
255 using preliminary data on a prior study of 15 patients with a mean (SD) for P2Y12 
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256 Reaction Units (PRU) of 257 (61.1). A sample size of 50 in each group would have 80% 
257 power to detect an effect size of 0.566 using a two-group t-test with a 5% two-sided 
258 significance level. This is equivalent to a difference of 34.6 units of PRU between the 
259 cangrelor and ticagrelor groups. Post-hoc analysis shows that 50 patients per group 
260 provides 95% power to demonstrate a 30% reduction in PRU at first coronary balloon 
261 inflation time in the cangrelor group compared to the ticagrelor group. 
262 RESULTS
263 Study Population
264 Patient, treatment and procedure characteristics are described in table 1 and table 2. 
265 Two hundred twenty six patients presenting with STEMI were screened, 117 
266 randomized. Of the 109 excluded patients, 42 had previously received a P2Y12 
267 inhibitor and 37 had suffered previous MI. Other exclusions included cardiogenic 
268 shock (n=13), oral anticoagulant therapy (n=8), lacking capacity for consent (n=4), 
269 history of bleeding (n=3) and renal failure requiring dialysis (n=2), (Figure 1). 
270 Seventeen subjects were withdrawn from the study after randomization due to either 
271 the use of GPIIb/IIIa inhibitors (cangrelor n=6, ticagrelor n=5, total n=11; 9.4%), 
272 extreme clinical instability (n=2) or the presence of an alternative diagnosis 
273 (myocarditis n=2; Takotsubo cardiomyopathy n=2). Of the 117 randomized patients, 
274 1 died after withdrawal from the study. After these exclusions/withdrawals, 100 
275 randomized patients were included for analysis (cangrelor n=50, ticagrelor n=50). All 
276 patients received P2Y12 inhibitors as per protocol. Of the 100 patients, 90 were 
277 assessed for microvascular function using IMR (ticagrelor n=45 cangrelor n=45) with 
278 hemodynamic instability precluding measurement in 10 subjects. Angiographic 
279 analysis was performed on all subjects and CMR at three months was performed in 75 
280 (cangrelor n=37, ticagrelor n=38). Reasons for not undertaking CMR included renal 
281 failure (n=2), lengthy intensive care unit stay (n=1), procedure intolerance/ 
282 claustrophobia (n=2) and 20 patients declined. Morphine for pain relief was 
283 administered to 37 out of 50 (74%) cangrelor-treated patients, at an average dose of 
284 9.7mg, and to 40 out of 50 (80%) ticagrelor-treated patients, at an average dose of 
285 8.5mg. The mean time from morphine administration to study drug loading was 60 
286 minutes in the cangrelor arm and 55 minutes in ticagrelor arm.
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287 All 100 patients survived to discharge. One patient underwent in-patient coronary 
288 artery bypass operation necessitating a prolonged intensive care unit stay. Two 
289 patients became hemodynamically unstable during PPCI and needed the insertion of 
290 intra-aortic balloon pump. 
291
292 Primary Endpoints 
293 Platelet Inhibition
294 At the time of initial coronary balloon inflation, cangrelor produced significantly 
295 greater P2Y12 inhibition, (cangrelor 145.2 ± 50.6 vs. ticagrelor 248.3 ± 55.1; p<0.001, 
296 Mean, SD). This difference was no longer apparent at 4 hours (cangrelor 158.1±92.1 
297 vs. ticagrelor 131.2±92.9; p= 0.15) and 24-36 hours after study drug administration 
298 (cangrelor 61.0±50.0 vs. ticagrelor 60.1±56.3 p= 0.93). (Figure 2) Whilst there was a 
299 slight numerical increasing PRU in patients within the cangrelor group after 
300 transitioning to ticagrelor (cangrelor 145.2 ± 50.6 to 158.1±92.1) this was not 
301 statistically significant, indicating that this transitioning period is safe in the context 
302 of STEMI. With the randomization and treatment allocation in the emergency setting, 
303 both drugs were given as soon as practicable after randomisation, before PPCI. The 
304 preparation time of IV cangrelor was longer than that for administering ticagrelor; this 
305 translated into a longer ticagrelor initiation-balloon inflation time than cangrelor 
306 initiation-balloon inflation time (23.0±12.8 minutes for cangrelor vs. 36.3±16.9 for 
307 ticagrelor; P<0.0001). At balloon inflation, 45 out of 50 (90%) cangrelor treated 
308 patients achieved an optimal PRU (<208 units). Only 11 out of 50 (22%) ticagrelor 
309 treated subjects were in range (P<0.0001). (Table 3) At 4 hours post initial drug 
310 dosing, 15 out of 50 ticagrelor-treated patients (30%) and 20 out of 50 cangrelor-
311 treated patients (40%) had PRU values above 208, indicating high-on treatment 
312 platelet reactivity (HPR). In the cangrelor treated group this measure was taken 2.5 
313 hours following transitional ticagrelor loading and 2 hours after the cangrelor infusion 
314 had ended. The administration of morphine did not influence the degree of P2Y12 
315 inhibition at the time of coronary balloon inflation in either of the treatment groups 
316 (p=0.48).
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317 Surrogate Endpoints 
318 Index of Microvascular Resistance and Coronary Flow Reserve 
319 The mean time from administration of study drugs to IMR measurement was 88 
320 minutes. Following PPCI, IMR was similar in each group, (Figure 3A), (cangrelor 30 
321 (22,58), ticagrelor 28 (21,40), median (IQR); p=0.52). Similarly, the proportion of 
322 patients with IMR greater than 40 (cangrelor 18 (40%) vs. ticagrelor 11(24%), p=0.11) 
323 was not different. CFR results were also similar between groups (Figure 3B) 
324 (cangrelor median (18) 1.3 (19), ticagrelor 1.4 (20) p=0.30). 
325 Angiographic Analysis
326 There was no significant difference in the occurrence of post-PCI MPG 3 (cangrelor 
327 n=31 vs. ticagrelor n=32; p=0.54) and TFG 3 (cangrelor n=38 vs. ticagrelor n=42; 
328 p=0.27) between treatment groups. Likewise, there was no difference in the mean 
329 cTFC (21.7±14.2 for cangrelor vs. 21.4±10.2 for ticagrelor; p=0.93). Suboptimal 
330 TIMI flow grades (1 and 2) were present at the end of the PPCI procedure in 12 
331 cangrelor-treated patients and 7 ticagrelor-treated patients.
332 EKG Analysis
333 At 90-120 minutes following PPCI, no difference was seen in STR between the 
334 cangrelor and ticagrelor groups (complete=32%, partial=11%, none=7% for cangrelor 
335 vs. complete=36%, partial=7%, none=7% for ticagrelor; p= 0.57). 
336 Myocardial Infarct Size
337 CMR was performed at a median of 13 weeks after PPCI in both of the groups (Figure 
338 3C;Table 4). Infarct scar was revealed on late gadolinium enhancement in 68 out of 
339 75 (90.6%) patients who had CMR performed (cangrelor 31, ticagrelor 37 patients). 
340 There was no difference in infarct size as a percentage of LV mass between groups 
341 (cangrelor 13.7 (7.7,17.5), ticagrelor 10.9 (6.6,17.5), Median, (IQR); p=0.61). 
342 Similarly, left ventricular ejection fraction was not different (cangrelor 56.50 
343 (47.50,59.25), ticagrelor 55 (44.50,61.50) median, (IQR); p=0.96). Peak troponin 
344 levels at 24-36 hours post drug administration did not differ significantly between the 
345 treatment groups (Table 4).
Page 13 of 74 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14
346 Safety Endpoints
347 Two out of 50 cangrelor-treated patients and 3 out of 50 ticagrelor-treated patients 
348 developed hematoma at the radial access site around 20-50 minutes following PPCI 
349 (Type 2 BARC). This was managed conservatively and required no surgical 
350 intervention in either of the treatment arms. One patient in the ticagrelor arm 
351 developed limiting shortness of breath 2 days after initiation necessitating 
352 replacement with clopidogrel, which resulted in complete resolution of symptoms.
353 DISCUSSION
354 This randomized-controlled and assessor blinded study assesses the effect of a 
355 strategy of IV cangrelor transitioning to ticagrelor, compared to ticagrelor standard 
356 therapy on P2Y12 inhibition; coronary microcirculation and infarct size in a STEMI 
357 population treated with PPCI. The main findings are as follows: 
358 Firstly, IV cangrelor, compared to oral ticagrelor produced a markedly greater P2Y12 
359 inhibition at the time of infarct-related artery balloon inflation during PPCI. 
360 Secondly, IV cangrelor was not shown to be superior to oral ticagrelor in improving 
361 coronary microcirculatory reperfusion as assessed by IMR and CFR and no difference 
362 was seen in terms of the angiographic markers of coronary reperfusion and STR. 
363 Similarly no significant difference was seen between groups in the initial infarct size 
364 assessed by peak troponin and the final infarct size assessed by CMR at 3 months. 
365 These results support our hypothesis that IV cangrelor when compared with oral 
366 ticagrelor will yield greater P2Y12 inhibition at the time of coronary balloon inflation 
367 by PPCI. This greater early P2Y12 inhibition did not appear to lead to improved 
368 microcirculatory function/perfusion, or result in a reduced myocardial infarct size. 
369 If the degree of peri-interventional P2Y12 inhibition in STEMI treatment is of 
370 significant importance, strategies to both provide strong inhibition and also limit the 
371 possible negative effect of transitioning to an oral agent might be valuable. Two 
372 recently published studies have investigated the pharmacodynamic effect of cangrelor 
373 compared to different ticagrelor loading regimens during PPCI. 
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374 In the first, 30 patients received ticagrelor loading prior to angiography and then were 
375 randomised in the catheter lab to either cangrelor or no additional antiplatelet 
376 treatment. [4] It showed markedly more potent P2Y12 inhibition (PRU) 15 minutes 
377 following loading in subjects treated with cangrelor. There was a suggestion, in this 
378 trial, of an increase in platelet reactivity following cessation of the cangrelor infusion 
379 with 4 out of 15 patients exhibiting an increase in PRU at 2-4 hours. The loading 
380 regimen used was in contrast to our current study, where cangrelor was administered 
381 as monotherapy before angiography and during PPCI in the cangrelor arm, and the 
382 transition to ticagrelor occurred following PPCI, with the oral agent being given 30 
383 minutes prior to cangrelor cessation.
384 In the CANTIC trial whereby 50 subjects received ticagrelor loading as crushed 
385 tablets at the time of randomisation to cangrelor or placebo, once again more potent 
386 P2Y12 inhibition was demonstrated in the cangrelor treated patients, particularly at the 
387 primary endpoint time of 30 minutes. [5] Interestingly, in this study with assessment 
388 of P2Y12 inhibition at 8 time points, no increase in PRU was seen after the cangrelor 
389 infusion was stopped, suggesting no rebound in platelet activity and no drug-drug 
390 interaction. These finding are in line with our study of 100 STEMI patients in which 
391 no significant increase in P2Y12 inhibition was evident in the cangrelor treated 
392 subjects, when measured at 4 hours after randomisation, following the transition from 
393 cangrelor to ticagrelor. This issue of transition from cangrelor to an oral agent was 
394 elegantly studied in more stable patients undergoing PCI in the ExcelsiorLOAD2 trial. 
395 Despite the previously demonstrated drug-drug interaction shown between the 
396 thienopyridine clopidogrel and cangrelor, prasugrel (and also ticagrelor), when given 
397 at the onset of the cangrelor infusion yielded very good levels of P2Y12 inhibition 
398 soon after cangrelor cessation seemingly preventing a clinically relevant gap in 
399 platelet inhibition cangrelor. [18]
400
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402 The paradigm of potent antiplatelet agents to improve STEMI PPCI outcomes and 
403 reduce myocardial infarct size
404 STEMI is associated with a high degree of intrinsic platelet activation, the level of 
405 which is associated with the magnitude of both subsequent antiplatelet therapy effect 
406 and clinical outcomes. [19] Furthermore, PPCI is the coronary interventional 
407 procedure associated with the highest frequency of severe thrombotic complications 
408 and therefore rapid and consistent platelet inhibition is a key objective in STEMI 
409 management [20]. Prasugrel and ticagrelor are potent and rapidly acting P2Y12 
410 inhibitors that reduce adverse ischemic events in STEMI patients when compared to 
411 clopidogrel. [3] The therapeutic effect of prasugrel and ticagrelor is markedly delayed 
412 in the context of STEMI, [3] and so PPCI is likely to be performed in the context of 
413 sub-optimal P2Y12 inhibition. We showed that over three quarters of study 
414 participants randomized to oral ticagrelor have a suboptimal level of P2Y12 inhibition 
415 at the time of first coronary balloon inflation.
416 Does potent antiplatelet activity at the time of reperfusion with PPCI matter?
417 There is theoretical concern about inadequate antiplatelet effect during PPCI. In the 
418 STEMI sub analyses of both the TRITON-TIMI 38 (prasugrel) and PLATO 
419 (ticagrelor) trials, the incidence of early stent thrombosis (in the first 24 hours) was 
420 similar between groups, possibly implicating delayed onset of action for these orally 
421 acting P2Y12 agents.  Suboptimal early P2Y12 inhibition may also be implicated in the 
422 PLATO STEMI subset finding that ticagrelor did not improve post PPCI STR and 
423 also that no increase in the incidence of post procedural TIMI 3 flow was seen with 
424 this agent. [21, 22] Attempts to circumvent this limitation of the oral route include 
425 upstream administration, [23] dose modification [24] and changes in formulation such 
426 as crushing tablets before administration. [25]
427 Cangrelor, the rapidly acting potent intravenous P2Y12 inhibitor might mitigate 
428 against the perceived failings of oral P2Y12 inhibition in the context of STEMI. It has 
429 been studied in three major clinical trials, each using clopidogrel as the comparator. 
430 CHAMPION PCI and CHAMPION PLATFORM both failed to meet their primary 
431 objective, whereas in the later CHAMPION PHOENIX trial, randomizing 10,942 
432 subjects with stable angina and ACS, cangrelor reduced the primary endpoint (a 
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433 composite of Death, MI, ischemia driven revascularization and stent thrombosis). In a 
434 pooled analysis of patient level data cangrelor was superior to clopidogrel in reducing 
435 the primary endpoint of all cause death, MI, ischemia driven revascularization at 48 
436 hours (OR 0.81, 95% CI 0.71-0.91, P=0.0007). Results in the 2891 subjects treated 
437 for STEMI were consistent with this, but did not reach significance (OR 0.84, 95%CI 
438 0.55-1.27 P=0.41). Of interest clopidogrel was given before PPCI in only 55.7% of 
439 subjects in this analysis. [26] The rate of intra-procedural stent thrombosis in 
440 clopidogrel treated patients was markedly higher than in the cangrelor treated patients. 
441 [26] Many have questioned whether the early antiplatelet advantage seen with
442 cangrelor vs. clopidogrel would be seen if a more rapidly acting and potent oral agent 
443 was used as the comparator and the results of our study inform this debate and adds to 
444 our knowledge regarding the utility of early P2Y12 inhibition in the setting of PPCI. 
445 Theoretically sound strategies that have failed to translate into improved myocardial 
446 tissue perfusion post PPCI include glycoprotein (GP) IIb/IIIa inhibitors and aspiration 
447 thrombectomy.[27] Ischemia reperfusion injury or other factors may be more 
448 important causes of impaired myocardial tissue perfusion post PPCI rather than distal 
449 microvascular thrombosis. 
450 Many other on-going lines of research aim to improve patient outcomes following 
451 PPCI. Changes in clinical pathways, mechanical reperfusion techniques and 
452 pharmacotherapy are all being investigated. The current study adds to our knowledge 
453 regarding the utility of early P2Y12 inhibition in the setting of PPCI. 
454 The principal finding of our study - that cangrelor leads to more potent P2Y12 
455 inhibition at the time of coronary balloon inflation during PPCI than oral ticagrelor- 
456 lends support to its use for STEMI patients undergoing PPCI if an oral agent cannot 
457 be administered. Such circumstances are relatively common; examples include 
458 intubated patients having suffered out of hospital cardiac arrest, those with severe 
459 nausea and patients in whom the diagnosis is uncertain prior to angiography who 
460 might need early surgical intervention. 
461 However, despite the impressive pharmacodynamic results achieved with cangrelor in 
462 our, and recent studies, the clinical significance for cangrelor vs. ticagrelor remains 
463 unclear. We were unable to demonstrate a significant difference in the tested 
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464 surrogate measures of STEMI outcome or in terms of final infarct size. The clinical 
465 importance of potent P2Y12 inhibition in the early course of STEMI treatment with 
466 PPCI remains to be determined and requires further investigation in larger scale 
467 clinical trials. 
468
469 Limitations 
470 This trial was an open label randomized trial and therefore subject to risk of operator 
471 bias. To minimise this risk, all surrogate endpoints were analyzed by researchers 
472 blinded to treatment allocation. 
473 Another principle limitation is the study size. The current study has randomized larger 
474 numbers than recently published trials of cangrelor vs. ticagrelor, but was not fully 
475 powered for the secondary surrogate endpoints assessing PPCI success. These 
476 secondary outcome findings should be regarded as hypothesis generating therefore.
477 Taking the primary endpoint of P2Y12 inhibition at first balloon inflation time, it 
478 should be noted that no baseline Verify-Now measures were taken before study drug 
479 administration, and so in the ticagrelor arm, where the sample was taken at an average 
480 of 36 minutes post drug loading, the limited effect seen might, in part, be related to 
481 baseline non-drug P2Y12 activity.  
482 Conclusions 
483 Cangrelor greatly increases P2Y12 inhibition at the time of coronary balloon inflation 
484 compared with ticagrelor in patients with STEMI undergoing PPCI. Our data suggest 
485 that cangrelor can be considered for patients undergoing PPCI not pre-treated with 
486 oral P2Y12 receptor inhibitors. This approach would allow bridging of the gap that 
487 results from the delayed onset of action of oral P2Y12 receptor inhibitors. 
488 This pharmacodynamic advantage did not translate into a measurable clinically 
489 relevant effect in the secondary endpoints, however these need to be interpreted with 
490 caution and should be seen as hypothesis generating only and can form the basis for 
491 future studies.
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Thrombosis and Haemostasis Figure Two
Figure 2. Box and whiskers plots showing comparison of the degree of P2Y12 inhibition measured by platelet reaction units at balloon inflation (vessel opening) time, 4 hours and 24-36 hours post antiplatelet drugs administration. Group data shown (median, IQR range). IQR = interquartile range, PRU= Platelet Reaction Units.
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Thrombosis and Haemostasis Figure Three
Figure 3. Graphs comparing the effect of cangrelor and ticagrelor on IMR (A) and CFR (B) immediately post index PPCI procedure, and total infarct size (C) by CMR imaging at three months follow up. Group (median and interquartile range) and individual data shown ( indicates cangrelor while  indicates ticagrelor). CFR = coronary reserve flow, CMR = cardiac magnetic resonance, IMR = index of microvascular resistance, PPCI = primary percutaneous coronary intervention
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Table 1 Patient characteristics 
Characteristic
All
(n = 100)
Cangrelor 
(n = 50)
Ticagrelor 
(n = 50)
Demographics 
  Age, years 62.3 ±13.4 61.2 ±13.9 63.4 ± 12.9
  Males 72 (72) 39 (78) 33 (66)
 BMI, kg/m2 28.3 ± 6.0 28.5 ± 6.3 28.1 ± 5.7
Smoking status
  Current smoker 50 (50) 26 (52) 24 (48)
  Former smoker 16 (16) 7 (14) 9 (18)
Medical history
  CVD Family history 31 (31) 18 (36) 13 (26)
  Diabetes 19 (19) 10 (20) 9 (18)
  Hypertension 44 (44) 20 (40) 24 (48)
  Hyperlipidemia 20 (20) 13 (26) 7 (14)
  Previous MI 0 0 0
  Previous CABG 0 0 0
  Previous TIA/CVA 0 0 0
  Previous PCI 4 (4) 1 (2) 3 (6)
  Pre-infarct angina 4 (4) 3 (6) 1 (2)
Admission blood tests
  Hemoglobin, g/L 138.2 ± 18.0 138.1 ± 16.6 138.4± 19.4
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  Neutrophils, 109 g/L 9.4 ± 3.6 9.6 ± 3.7 9.2 ± 3.5
  Platelet count, 109 g/L 250.6 ± 65.9 245.8 ± 66.0 255.5 ± 66.1
  WCC, 109 g/L 12.2 ± 4.1 12.4 ± 4.4 12.0 ± 3.8
Angiographic variables
  MI Localisation
    Anterior 31 (31) 13 (26) 18 (36)
    Inferior 61 (61) 32 (64) 29 (58)
    Infero-lateral 1 (1) 0 1 (2)
    Lateral 5 (5) 4 (8) 1 (2)
    Posterior 2 (2) 1 (2) 1 (2)
  Culprit Vessel
    LMS 1 (1) 0 1 (2)
    LAD 31 (31) 15 (30) 16 (32)
    LCX 14 (14) 8 (16) 6 (12)
    INT 1 (1) 0 1 (2)
    RCA 53 (53) 27 (54) 26 (52)
  Number of vessels diseased
    0 1 (1) 0 1 (2)
    1 28 (28) 11 (22) 17 (34)
    2 30 (30) 16 (32) 14 (28)
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    3 41 (41) 23 (46) 18 (36)
  Number of vessels treated
    0 2 (2) 1 (2) 1 (2)
    1 89 (89) 42 (84) 47 (94)
    2 9 (9) 7 (14) 2 (4)
Values are mean ± SD, n (%) or median (IQR) as appropriate. IQR = interquartile range; SD = standard 
deviation; BMI = body mass index; CABG = coronary artery bypass graft; CVA = cerebrovascular 
accident; CVD = cardiovascular disease; INT = Intermediate artery; LAD = left anterior descending 
artery; LCX = left circumflex artery; LMS = Left main stem; MI = Myocardial Infarction; PCI = 
percutaneous coronary intervention; RCA = right coronary artery; TIA = transient ischemic attack; 
WCC = white cell count. 
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Table 2 Treatment and procedure characteristics 
Characteristic
All
(n = 100)
Cangrelor 
(n = 50)
Ticagrelor 
(n = 50)
p value
Call to balloon time, minutes 121 [102, 140] 116 [100, 136] 126 [106, 150] 0.16
Door to balloon time, minutes 57 [45, 71] 53 [45, 71] 59 [44, 70] 0.83
Treatment duration, minutes 28 [20, 37] 24 [12, 30] 33 [23, 48] <0.001
Ischemia duration, minutes 192 [143, 289] 164 [133, 233] 195 [148, 345] 0.26
Morphine given 77 (77) 37 (74) 40 (80) 0.48
Total heparin, units
8000 [6500, 
10000]
8500 [5000, 
10000]
8000 [7000, 
10000]
0.83
Total length of stent, mm 42.1 ± 22.1 43.2 ± 22.9 40.8 ± 21.4 0.59
Thrombectomy 14 (14) 7 (14) 7 (14) 1.00
Values are mean ± SD, n (%) or median [IQR] as appropriate. P-values are from Two-sample t test, 
Wilcoxon sum rank test or Chi-squared test as appropriate. IQR = interquartile range.
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Table 3 Comparison of P2Y12 reaction units (PRU) at coronary reperfusion (balloon inflation) time, by 
treatment group. 
Characteristic Category
Cangrelor 
(n = 50)
Ticagrelor 
(n = 50)
p value
PRU units at balloon inflation <=208 45   (90%) 11   (22%) <0.0001
>208 5   (10%) 39   (78%)
P-values from chi-squared test. PRU= platelet reaction units.
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Table 4 Infarct size by CMR and peak troponin levels
Characteristic
All
(n = 64)
Cangrelor 
(n = 29)
Ticagrelor 
(n = 25)
p value
Infarct size (CMR, %) 11.8 [ 6.8,17.5] 13.7 [7.7, 17.5] 10.9 [6.6, 17.5] 0.61
Infarct size (Peak Troponin, 
ng/L)
29556 [13879, 
58988]
37169 [14230, 
56740]
23896 [13663, 
66565]
0.84
Values are median [IQR]. P-values are from Wilcoxon sum rank test. CMR = cardiac magnetic 
resonance; IQR = interquartile range
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